Group 1: Company Overview - As of May 19, 2023, the number of shareholders is 31,819 [2] - The company focuses on the production of ibuprofen and its derivatives, aiming to establish a global production base for antipyretic and analgesic drugs [3] Group 2: Future Projects and Developments - The company plans to advance the construction of projects with an annual capacity of 5,000 tons of ibuprofen and 200 tons of ibuprofen lysinate [3] - It aims to enhance its product system in cardiovascular, anti-tumor, and anticholinergic drugs, with projects like 10 tons/year of abiraterone acetate and 2 tons/year of imatinib mesylate [3] - The company is also working on the development of various formulations, including sustained-release ibuprofen capsules and injection products [3] Group 3: Sales and Marketing Strategy - The sales model for raw materials is primarily direct sales, supplemented by distribution, while formulations are sold domestically through a distribution model [4] - The company emphasizes a customer-centric sales philosophy [4] Group 4: Research and Development Focus - The company prioritizes new drug research, particularly in ibuprofen derivatives and specialty raw materials for cardiovascular and anti-tumor applications [3] - Currently, there are no traditional Chinese medicine products or research initiatives [4] Group 5: Vision and Goals - The company aims to become a significant domestic base for non-steroidal anti-inflammatory raw materials and specialty raw materials, promoting synergistic development between raw materials and formulations [4]
亨迪药业(301211) - 亨迪药业2023年湖北辖区上市公司投资者网上集体接待日活动信息